Ferulic acid decreases cell viability and colony formation while inhibiting migration of MIA PaCa-2 human pancreatic cancer cells in vitro

Gene

Volumn 576, Issue 1, 2016, Pages 476-482

  Fahrioğlu, Umut ^a   Dodurga, Yavuz ^b   Elmas, Levent ^b   Seçme, Mücahit ^b  

^a NEAR EAST UNIVERSITY   (Turkey)

^b PAMUKKALE UNIVERSITY   (Turkey)

Author keywords

Apoptotic genes; Cell cycle genes; Ferulic acid; Pancreatic cancer; Treatment

Indexed keywords

CASPASE 10; CASPASE 3; CASPASE 8; CASPASE 9; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FERULIC ACID; GELATINASE A; GELATINASE B; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; PROTEIN KINASE B; PROTEIN NOXA; PROTEIN P16; PROTEIN P21; PROTEIN P53; PUMA PROTEIN; RETINOBLASTOMA PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRYPAN BLUE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; COUMARIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL CYCLE; CELL INVASION; CELL VIABILITY; CELL VIABILITY ASSAY KIT; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY ASSAY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC50; IN VITRO STUDY; MIGRATION INHIBITION; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TUMOR INVASION; DRUG EFFECTS; NEOPLASM METASTASIS; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE; WOUND HEALING;

CELL LINE, TUMOR; COUMARIC ACIDS; HUMANS; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; WOUND HEALING;

EID: 84949580208     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2015.10.061     Document Type: Article

References (36)

1. Anselmi C., Centini M., Andreassi M., Buonocore A., La Rosa C., Facino R.M., Tsuno F. Conformational analysis: a tool for the elucidation of the antioxidant properties of ferulic acid derivatives in membrane models. J. Pharm. Biomed. Anal. 2004, 35(5):1241-1249. 10.1016/j.jpba.2004.04.008.
2. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434(7035):913-917. 10.1038/nature03443.
3. Chang C.J., Chiu J.H., Tseng L.M., Chang C.H., Chien T.M., Wu C.W., Lui W.Y. Modulation of HER2 expression by ferulic acid on human breast cancer MCF7 cells. Eur. J. Clin. Investig. 2006, 36(8):588-596. 10.1111/j.1365-2362.2006.01676.x.
4. Choi Y.E., Park E. Ferulic acid in combination with PARP inhibitor sensitizes breast cancer cells as chemotherapeutic strategy. Biochem. Biophys. Res. Commun. 2015, 458(3):520-524. 10.1016/j.bbrc.2015.01.147.
5. Çitişli V., Dodurga Y., Eroğlu C., Seçme M., Avci Ç.B., Şatiroğlu-Tufan N.L. Temozolomide may induce cell cycle arrest by interacting with URG4/URGCP in SH-SY5Y neuroblastoma cells. Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine 2015, 10.1007/s13277-015-3373-7.
6. Dodurga Y., Gundogdu G., Tekin V., Koc T., Satiroglu-Tufan N.L., Bagci G., Kucukatay V. Valproic acid inhibits the proliferation of SHSY5Y neuroblastoma cancer cells by downregulating URG4/URGCP and CCND1 gene expression. Mol. Biol. Rep. 2014, 41(7):4595-4599. 10.1007/s11033-014-3330-3.
7. Eitsuka T., Tatewaki N., Nishida H., Kurata T., Nakagawa K., Miyazawa T. Synergistic inhibition of cancer cell proliferation with a combination of δ-tocotrienol and ferulic acid. Biochem. Biophys. Res. Commun. 2014, 453(3):606-611. 10.1016/j.bbrc.2014.09.126.
8. Eroğlu C., Seçme M., Bağci G., Dodurga Y. Assessment of the anticancer mechanism of ferulic acid via cell cycle and apoptotic pathways in human prostate cancer cell lines. Tumor Biology 2015, 10.1007/s13277-015-3689-3.
9. Fang H.-Y., Wang H.-M., Chang K.-F., Hu H.-T., Hwang L.-J., Fu T.-F., Chen B.-H. Feruloyl-L-arabinose attenuates migration, invasion and production of reactive oxygen species in H1299 lung cancer cells. Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association 2013, 58:459-466. 10.1016/j.fct.2013.05.019.
10. Farmer H., McCabe N., Lord C.J., Tutt A.N.J., Johnson D.A., Richardson T.B., Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434(7035):917-921. 10.1038/nature03445.
11. Hartland S.N., Murphy F., Aucott R.L., Abergel A., Zhou X., Waung J., Iredale J.P. Active matrix metalloproteinase-2 promotes apoptosis of hepatic stellate cells via the cleavage of cellular N-cadherin. Liver International: Official Journal of the International Association for the Study \of the Liver 2009, 29(7):966-978. 10.1111/j.1478-3231.2009.02070.x.
12. Hemaiswarya S., Doble M. Combination of phenylpropanoids with 5-fluorouracil as anti-cancer agents against human cervical cancer (HeLa) cell line. Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 2013, 20(2):151-158. 10.1016/j.phymed.2012.10.009.
13. Hollman P.C., Katan M.B. Bioavailability and health effects of dietary flavonols in man. Archives of Toxicology. Supplement.=Archiv Fur Toxikologie. Supplement 1998, 20:237-248. 10.1080/10715769900301351.
14. Hou Y.-Z., Yang J., Zhao G.-R., Yuan Y.-J. Ferulic acid inhibits vascular smooth muscle cell proliferation induced by angiotensin II. Eur. J. Pharmacol. 2004, 499(1-2):85-90. 10.1016/j.ejphar.2004.07.107.
15. Janicke B., Hegardt C., Krogh M., Onning G., Akesson B., Cirenajwis H.M., Oredsson S.M. The antiproliferative effect of dietary fiber phenolic compounds ferulic acid and p-coumaric acid on the cell cycle of Caco-2 cells. Nutr. Cancer 2011, 63(4):611-622. 10.1080/01635581.2011.538486.
16. Joshi G., Perluigi M., Sultana R., Agrippino R., Calabrese V., Butterfield D.A. In vivo protection of synaptosomes by ferulic acid ethyl ester (FAEE) from oxidative stress mediated by 2,2-azobis(2-amidino-propane)dihydrochloride (AAPH) or Fe(2+)/H(2)O(2): insight into mechanisms of neuroprotection and relevance to oxidative stress-re. Neurochem. Int. 2006, 48(4):318-327. 10.1016/j.neuint.2005.11.006.
17. Karthikeyan S., Kanimozhi G., Prasad N.R., Mahalakshmi R. Radiosensitizing effect of ferulic acid on human cervical carcinoma cells in vitro. Toxicol. in Vitro 2011, 25(7):1366-1375. 10.1016/j.tiv.2011.05.007.
18. Kawabata K., Yamamoto T., Hara A., Shimizu M., Yamada Y., Matsunaga K., Mori H. Modifying effects of ferulic acid on azoxymethane-induced colon carcinogenesis in F344 rats. Cancer Lett. 2000, 157(1):15-21. 10.1016/S0304-3835(00)00461-4.
19. Lavictoire S.J., Parolin D.a.E., Klimowicz A.C., Kelly J.F., Lorimer I.a.J. Interaction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRvIII. J. Biolumin. Chemilumin. 2003, 278(7):5292-5299. 10.1074/jbc.M209494200.
20. Lavoie J.N., Allemain G.L., Müller R., Pouysségur J., Lavoie N., Brunet A., Pouysse J. Cell biology and metabolism: cyclin D1 expression is regulated positively by the p42/p44 MAPK and negatively by the p38/HOG MAPK pathway cyclin D1 expression is regulated positively by the p42/p44 MAPK and negatively by the p38/HOG MAPK pathway *, 1996, 271(34):20608-20616.
21. Lin C.M., Chiu J.H., Wu I.H., Wang B.W., Pan C.M., Chen Y.H. Ferulic acid augments angiogenesis via VEGF, PDGF and HIF-1α. J. Nutr. Biochem. 2010, 21(7):627-633. 10.1016/j.jnutbio.2009.04.001.
22. Mancuso C., Santangelo R. Ferulic acid: pharmacological and toxicological aspects. Food Chem. Toxicol. 2014, 65:185-195. 10.1016/j.fct.2013.12.024.
23. Musgrove E.A., Caldon C.E., Barraclough J., Stone A., Sutherland R.L. Cyclin D as a therapeutic target in cancer. nature reviews. Cancer 2011, 11(8):558-572. 10.1038/nrc3090.
24. Narasimhan A., Chinnaiyan M., Karundevi B. Ferulic acid regulates hepatic GLUT2 gene expression in high fat and fructose-induced type-2 diabetic adult male rat. Eur. J. Pharmacol. 2015, 1-7. 10.1016/j.ejphar.2015.04.043.
25. Ou L., Kong L.-Y., Zhang X.-M., Niwa M. Oxidation of ferulic acid by Momordica charantia peroxidase and related anti-inflammation activity changes. Biol. Pharm. Bull. 2003, 26(11):1511-1516. 10.1248/bpb.26.1511.
26. Peng C.C., Chyau C.C., Wang H.E., Chang C.H., Chen K.C., Chou K.Y., Peng R.Y. Cytotoxicity of ferulic acid on T24 cell line differentiated by different microenvironments. BioMed Research International 2013, 2013. 10.1155/2013/579859.
27. Peurala E., Koivunen P., Haapasaari K.-M., Bloigu R., Jukkola-Vuorinen A. The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer. Breast Cancer Research: BCR 2013, 15(1):R5. 10.1186/bcr3376.
28. Rader J., Russell M.R., Hart L.S., Nakazawa M.S., Belcastro L.T., Martinez D., Maris J.M. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin. Cancer Res. 2013, 19(22):6173-6182. 10.1158/1078-0432.CCR-13-1675.
29. Reynolds R.B., Folloder J. Clinical management of pancreatic cancer. Journal of the Advanced Practitioner in Oncology 2015, 5(5):356-364. Retrieved from http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4457174&tool=pmcentrez&rendertype=abstract.
30. Rukkumani R., Aruna K., Suresh Varma P., Menon V.P. Influence of ferulic acid on circulatory prooxidant - antioxidant status during alcohol and PUFA induced toxicity. J. Physiol. Pharmacol. 2004, 55(3):551-561.
31. Seicean A. New targeted therapies in pancreatic cancer. World J. Gastroenterol. 2015, 21(20):6127. 10.3748/wjg.v21.i20.6127.
32. Sherr C.J. G1 phase progression: cycling on cue. Cell 1994, 79(4):551-555. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/7954821.
33. Wang J., Yuan Z., Zhao H., Ju D., Chen Y., Chen X., Zhang J. Ferulic acid promotes endothelial cells proliferation through up-regulating cyclin D1 and VEGF. J. Ethnopharmacol. 2011, 137(2):992-997. 10.1016/j.jep.2011.07.019.
34. Xu T., Pan Z., Dong M., Yu C., Niu Y. Ferulic acid suppresses activation of hepatic stellate cells through ERK1/2 and Smad signaling pathways in vitro. Biochem. Pharmacol. 2015, 93(1):49-58. 10.1016/j.bcp.2014.10.016.
35. Yang J., Liu X., Bhalla K., Kim C.N., Ibrado A.M., Cai J., Wang X. Prevention of Apoptosis by Bcl-2: Release of Cytochrome C From Mitochondria Blocked 1997, 275:1129-1132. Science, New York, N.Y. 10.1126/science.275.5303.1129.
36. Zhu Y.-Y., Yuan Z. Pancreatic cancer stem cells. American Journal of Cancer Research 2015, 5(3):894-906. Retrieved from http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4449425&tool=pmcentrez&rendertype=abstract.